Kainuo Zhang, Miaomiao Gao, Chenqi Cao, Mengxin Zhang, Waqar Ahmad, Ahmed Rady, Badr Aldahmash, Tianze Zhu, Shahin Shah Khan, Luo Liu
{"title":"利用蜡样芽孢杆菌新型焦酰基转移酶强化2′-焦酰基乳糖生物合成途径。","authors":"Kainuo Zhang, Miaomiao Gao, Chenqi Cao, Mengxin Zhang, Waqar Ahmad, Ahmed Rady, Badr Aldahmash, Tianze Zhu, Shahin Shah Khan, Luo Liu","doi":"10.3389/fbioe.2025.1569597","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>2'-Fucosyllactose (2'-FL) is an oligosaccharide that can be synthesized in the human body and is known for its health-promoting and prebiotic effects. The biosynthesis of 2'-FL using microorganisms has received attention recently due to its increased application in nutritional and medical infant formulations.</p><p><strong>Methods: </strong>This work attempts the new application of <i>Bacillus cereus</i> α-1,2-fucosyltransferase (FutCB) in the <i>de novo</i> synthesis of 2'-FL in <i>Escherichia coli</i> (<i>E. coli</i>). Additionally, knocking out the <i>LacZ</i> and <i>WaaF</i> genes alongside overexpression of the key gmd, manB, wcaG, and manC genes enhances the availability of the necessary precursors GDP-L-fucose and lactose for the synthesis of 2'-FL.</p><p><strong>Results and discussion: </strong>The use of constitutive promoters achieved better control over the production of 2'-FL during fed-batch fermentation. After 64 h of fermentation, the modified <i>E. coli</i> strains produced 121.4 g/L 2'-FL with a yield of 1.90 g/L/h, resulting in an impressive 2'-FL output. These results together indicate the potential of large-scale, high-yield production of 2'-FL and form a basis of much more refinement to be done. The next step will focus on maximum substrate utilization, alteration of gene regulation, and improvement of commercial-scale synthesis.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1569597"},"PeriodicalIF":4.3000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075129/pdf/","citationCount":"0","resultStr":"{\"title\":\"Intensification of 2'-Fucosyllactose biosynthesis pathway by using a novel fucosyltransferase from <i>Bacillus cereus</i>.\",\"authors\":\"Kainuo Zhang, Miaomiao Gao, Chenqi Cao, Mengxin Zhang, Waqar Ahmad, Ahmed Rady, Badr Aldahmash, Tianze Zhu, Shahin Shah Khan, Luo Liu\",\"doi\":\"10.3389/fbioe.2025.1569597\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>2'-Fucosyllactose (2'-FL) is an oligosaccharide that can be synthesized in the human body and is known for its health-promoting and prebiotic effects. The biosynthesis of 2'-FL using microorganisms has received attention recently due to its increased application in nutritional and medical infant formulations.</p><p><strong>Methods: </strong>This work attempts the new application of <i>Bacillus cereus</i> α-1,2-fucosyltransferase (FutCB) in the <i>de novo</i> synthesis of 2'-FL in <i>Escherichia coli</i> (<i>E. coli</i>). Additionally, knocking out the <i>LacZ</i> and <i>WaaF</i> genes alongside overexpression of the key gmd, manB, wcaG, and manC genes enhances the availability of the necessary precursors GDP-L-fucose and lactose for the synthesis of 2'-FL.</p><p><strong>Results and discussion: </strong>The use of constitutive promoters achieved better control over the production of 2'-FL during fed-batch fermentation. After 64 h of fermentation, the modified <i>E. coli</i> strains produced 121.4 g/L 2'-FL with a yield of 1.90 g/L/h, resulting in an impressive 2'-FL output. These results together indicate the potential of large-scale, high-yield production of 2'-FL and form a basis of much more refinement to be done. The next step will focus on maximum substrate utilization, alteration of gene regulation, and improvement of commercial-scale synthesis.</p>\",\"PeriodicalId\":12444,\"journal\":{\"name\":\"Frontiers in Bioengineering and Biotechnology\",\"volume\":\"13 \",\"pages\":\"1569597\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075129/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Bioengineering and Biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.3389/fbioe.2025.1569597\",\"RegionNum\":3,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1569597","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Intensification of 2'-Fucosyllactose biosynthesis pathway by using a novel fucosyltransferase from Bacillus cereus.
Introduction: 2'-Fucosyllactose (2'-FL) is an oligosaccharide that can be synthesized in the human body and is known for its health-promoting and prebiotic effects. The biosynthesis of 2'-FL using microorganisms has received attention recently due to its increased application in nutritional and medical infant formulations.
Methods: This work attempts the new application of Bacillus cereus α-1,2-fucosyltransferase (FutCB) in the de novo synthesis of 2'-FL in Escherichia coli (E. coli). Additionally, knocking out the LacZ and WaaF genes alongside overexpression of the key gmd, manB, wcaG, and manC genes enhances the availability of the necessary precursors GDP-L-fucose and lactose for the synthesis of 2'-FL.
Results and discussion: The use of constitutive promoters achieved better control over the production of 2'-FL during fed-batch fermentation. After 64 h of fermentation, the modified E. coli strains produced 121.4 g/L 2'-FL with a yield of 1.90 g/L/h, resulting in an impressive 2'-FL output. These results together indicate the potential of large-scale, high-yield production of 2'-FL and form a basis of much more refinement to be done. The next step will focus on maximum substrate utilization, alteration of gene regulation, and improvement of commercial-scale synthesis.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.